Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Verisante Technology Inc. V.VRS


Primary Symbol: V.VER.H

Verisante Technology Inc is a Canada based medical device company. It is engaged in commercializing medical systems for the early detection of cancer. The products of the company are Verisante Aura which is for skin cancer detection and Verisante Core which is for lung, colon and cervical cancer detection. It utilizes a cancer detection platform while the operating software and probe technology. The group generates revenue from the sale and renting of its medical devices.


TSXV:VER.H - Post by User

Bullboard Posts
Post by Kantenahon Feb 11, 2008 5:49pm
270 Views
Post# 14353099

Vote of confidence from Versant

Vote of confidence from VersantOK... I realize that this is a biased source, but nonetheless it is reassuring to hear some confident statements leading into Wednesday's earnings announcement.  Here is a clip from a report issued today (Feb. 11/08) from Neil Linsdell from Versant Partners - I'm sorry but I don't have access to the full report (perhaps someone else could fill us in).

"Results for fiscal Q1, ended December 31, will be released on Wednesday, February 13. This will be the first period with a full quarter of contribution from the Med-Eng acquisition. We expect record results as the company shows financials that will include the fully integrated Med-Eng business for the first time. We expect the company to easily meet our forecasts based on previous guidance and delivery against the backlog. We maintain a BUY recommendation and target price of $10.50 using an 8× EV/EBITDA... "

Neil is about as close to "insider information" as we can get.  His words sound good to me.

-K
Bullboard Posts